Cardiovascular disease mortality after chemotherapy or surgery for testicular nonseminoma: A population-based study

Journal of Clinical Oncology

Volumn 33, Issue 28, 2015, Pages 3106-3114

  Fung, Chunkit ^a   Fossa, Sophie D ^b   Milano, Michael T ^a   Sahasrabudhe, Deepak M ^a   Peterson, Derick R ^a   Travis, Lois B ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CISPLATIN; ETOPOSIDE; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER SURGERY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR DISEASE; HEART DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; RISK FACTOR; STANDARDIZED MORTALITY RATIO; TESTIS NONSEMINOMA CANCER; ADVERSE EFFECTS; CANCER REGISTRY; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; COMPARATIVE STUDY; EPIDEMIOLOGY; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; NEOPLASMS, GERM CELL AND EMBRYONAL; ORCHIECTOMY; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; TESTICULAR NEOPLASMS; TIME FACTOR; TREATMENT OUTCOME; UNITED STATES;

ADULT; ANTINEOPLASTIC AGENTS; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASMS, GERM CELL AND EMBRYONAL; ORCHIECTOMY; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; RISK FACTORS; SEER PROGRAM; TESTICULAR NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84944250648     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.60.3654     Document Type: Article

References (51)

1. Siegel R, Ma J, Zou Z, et al: Cancer statistics, 2014. CA Cancer J Clin 64: 9-29, 2014
2. Einhorn LH, Donohue J: Cisdiamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med 87: 293-298, 1977
3. Hanna N, Einhorn LH: Testicular cancer: A reflection on 50 years of discovery. J Clin Oncol 32: 3085-3092, 2014
4. Verdecchia A, Francisci S, Brenner H, et al: Recent cancer survival in Europe: A 2000-02 period analysis of EUROCARE-4 data. Lancet Oncol 8: 784-796, 2007
5. Travis LB, Ng AK, Allan JM, et al: Second malignant neoplasms and cardiovascular disease following radiotherapy. J Natl Cancer Inst 104: 357-370, 2012
6. Haugnes HS, Wethal T, Aass N, et al: Cardiovascular risk factors and morbidity in long-Term survivors of testicular cancer: A 20-year follow-up study. J Clin Oncol 28: 4649-4657, 2010
7. Huddart RA, Norman A, Shahidi M, et al: Cardiovascular disease as a long-Term complication of treatment for testicular cancer. J Clin Oncol 21: 1513-1523, 2003
8. Meinardi MT, Gietema JA, van der Graaf WT, et al: Cardiovascular morbidity in long-Term survivors of metastatic testicular cancer. J Clin Oncol 18: 1725-1732, 2000
9. van den Belt-Dusebout AW, de Wit R, Gietema JA, et al: Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 25: 4370-4378, 2007
10. van den Belt-Dusebout AW, Nuver J, de Wit R, et al: Long-Term risk of cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 24: 467-475, 2006
11. Dieckmann KP, Gerl A, Witt J, et al: Myocardial infarction and other major vascular events during chemotherapy for testicular cancer. Ann Oncol 21: 1607-1611, 2010
12. O'Reilly A, MacEneaney P, Mayer N, et al: Testicular cancer and platinum: A double-edged sword. J Clin Oncol 32: E46-e48, 2014
13. Osswald M, Harlan LC, Penson D, et al: Treatment of a population based sample of men diagnosed with testicular cancer in the United States. Urol Oncol 27: 604-610, 2009
14. Travis LB, Ng A, Allan JM, et al: Report No. 170: Second Primary Cancers and Cardiovascular Disease After Radiation Therapy. Bethesda, MD, National Council on Radiation Protection and Measurements, 2011
15. Paasche-Orlow MK, Parker RM, Gazmararian JA, et al: The prevalence of limited health literacy. J Gen Intern Med 20: 175-184, 2005
16. Fosså SD, Cvancarova M, Chen L, et al: Adverse prognostic factors for testicular cancerspecific survival: A population-based study of 27,948 patients. J Clin Oncol 29: 963-970, 2011
17. Surveillance, Epidemiology, and End Results Program: SEER Cause of Death Recode 1969. Bethesda, MD, National Cancer Institute, 2002
18. Centers for Disease Control and Prevention: National Center for Health Statistics. http://www.cdc.gov/nchs/
19. Youn P, Milano MT, Constine LS, et al: Longterm cause-specific mortality in survivors of adolescent and young adult bone and soft tissue sarcoma: A population-based study of 28,844 patients. Cancer 120: 2334-2342, 2014
20. Liddell FD: Simple exact analysis of the standardised mortality ratio. J Epidemiol Community Health 38: 85-88, 1984
21. Einhorn LH: Testicular cancer as a model for a curable neoplasm: The Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 41: 3275-3280, 1981
22. Koton S, Schneider AL, Rosamond WD, et al: Stroke incidence and mortality trends in US communities, 1987 to 2011. JAMA 312: 259-268, 2014
23. Feldman DR, Schaffer WL, Steingart RM: Late cardiovascular toxicity following chemotherapy for germ cell tumors. J Natl Compr Canc Netw 10: 537-544, 2012
24. Nuver J, Smit AJ, Sleijfer DT, et al: Microalbuminuria, decreased fibrinolysis, and inflammation as early signs of atherosclerosis in long-Term survivors of disseminated testicular cancer. Eur J Cancer 40: 701-706, 2004
25. Nuver J, Smit AJ, van der Meer J, et al: Acute chemotherapy-induced cardiovascular changes in patients with testicular cancer. J Clin Oncol 23: 9130-9137, 2005
26. Togna GI, Togna AR, Franconi M, et al: Cisplatin triggers platelet activation. Thromb Res 99: 503-509, 2000
27. Turlapaty PD, Altura BM: Magnesium deficiency produces spasms of coronary arteries: Relationship to etiology of sudden death ischemic heart disease. Science 208: 198-200, 1980
28. van Schinkel LD, Willemse PM, van der Meer RW, et al: Chemotherapy for testicular cancer induces acute alterations in diastolic heart function. Br J Cancer 109: 891-896, 2013
29. Vogelzang NJ, Torkelson JL, Kennedy BJ: Hypomagnesemia, renal dysfunction, and Raynaud's phenomenon in patients treated with cisplatin, vinblastine, and bleomycin. Cancer 56: 2765-2770, 1985
30. Seng S, Liu Z, Chiu SK, et al: Risk of venous thromboembolism in patients with cancer treated with cisplatin: A systematic review and metaanalysis. J Clin Oncol 30: 4416-4426, 2012
31. Chew HK, Wun T, Harvey D, et al: Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 166: 458-464, 2006
32. Sallah S, Wan JY, Nguyen NP: Venous thrombosis in patients with solid tumors: Determination of frequency and characteristics. Thromb Haemost 87: 575-579, 2002
33. Hinton S, Catalano PJ, Einhorn LH, et al: Cisplatin, etoposide and either bleomycin or ifosfamide in the treatment of disseminated germ cell tumors: Final analysis of an intergroup trial. Cancer 97: 1869-1875, 2003
34. Kondagunta GV, Bacik J, Bajorin D, et al: Etoposide and cisplatin chemotherapy for metastatic good-risk germ cell tumors. J Clin Oncol 23: 9290-9294, 2005
35. Nichols CR, Catalano PJ, Crawford ED, et al: Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: An Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study. J Clin Oncol 16: 1287-1293, 1998
36. Williams SD, Birch R, Einhorn LH, et al: Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 316: 1435-1440, 1987
37. Alanee SR, Feldman DR, Russo P, et al: Long-Term mortality in patients with germ cell tumors: Effect of primary cancer site on cause of death. Urol Oncol 32: 26.e9-e15, 2014
38. Khorana AA, Kuderer NM, Culakova E, et al: Development and validation of a predictive model for chemotherapy-Associated thrombosis. Blood 111: 4902-4907, 2008
39. Moore RA, Adel N, Riedel E, et al: High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: A large retrospective analysis. J Clin Oncol 29: 3466-3473, 2011
40. Srikanthan A, Tran B, Beausoleil M, et al: Large retroperitoneal lymphadenopathy as a predictor of venous thromboembolism in patients with disseminated germ cell tumors treated with chemotherapy. J Clin Oncol 33: 582-587, 2015
41. Go AS, Mozaffarian D, Roger VL, et al: Heart disease and stroke statistics-2014 update: A report from the American Heart Association. Circulation 129: E28-e292, 2014
42. Beard CJ, Travis LB, Chen MH, et al: Outcomes in stage I testicular seminoma: A population-based study of 9193 patients. Cancer 119: 2771-2777, 2013
43. Zagars GK, Ballo MT, Lee AK, et al: Mortality after cure of testicular seminoma. J Clin Oncol 22: 640-647, 2004
44. Oldenburg J, Martin JM, Fosså SD: Late relapses of germ cell malignancies: Incidence, management, and prognosis. J Clin Oncol 24: 5503-5511, 2006
45. Mensah GA, Mokdad AH, Ford ES, et al: State of disparities in cardiovascular health in the United States. Circulation 111: 1233-1241, 2005
46. Johnson-Lawrence V, Kaplan G, Galea S: Socioeconomic mobility in adulthood and cardiovascular disease mortality. Ann Epidemiol 23: 167-171, 2013
47. Robles TF, Slatcher RB, Trombello JM, et al: Marital quality and health: A meta-Analytic review. Psychol Bull 140: 140-187, 2014
48. Williams SD, Einhorn LH: Brain metastases in disseminated germinal neoplasms: Incidence and clinical course. Cancer 44: 1514-1516, 1979
49. Travis LB, Beard C, Allan JM, et al: Testicular cancer survivorship: Research strategies and recommendations. J Natl Cancer Inst 102: 1114-1130, 2010
50. Bajorin DF: The graying of testis cancer patients: What have we learned? J Clin Oncol 25: 4341-4343, 2007
51. Lyman GH, Khorana AA, Kuderer NM, et al: Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 31: 2189-2204, 2013